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ABSTRACT 
HIV-1 associated neurocognitive disorder (HAND) is one of the major HIV-1 co-
morbidities prevalent around the world. Early during HIV-1 infection, virus crosses the blood - 
brain barrier (BBB) and enters central nervous system (CNS) through infiltrating infected 
monocytes/macrophages. These infiltrating infected monocytes/macrophages serve as the source 
to initiate secondary infection of resident monocytic cells and glial cells in CNS. Neurons are not 
directly infected by HIV-1 virus. However, pro-inflammatory cytokines and chemokines as well 
as viral proteins released by infected/exposed immune and glial cells are neurotoxic and contribute 
to the neuronal stress and apoptosis. Nearly more than half of individuals living with HIV-1 
infection present with some degree of neuronal impairment. Currently, no treatment is available to 
prevent or treat HAND. Thus, devising a strategy to manage HAND progression and improve the 
quality of life in HIV-1 positive population will be highly valuable and is of great public health 
significance. 
MicroRNAs are small non-coding RNAs which play an important role in post-
transcriptional regulation. Previous studies in our laboratory have identified specific miRNAs 
that may have a neuro-protective role. In this study, my goal is to evaluate the role of these 
candidate miRNAs on inflammatory response of monocytes/macrophages and microglia during 
 
v  
HIV-1 infection. I hypothesize that these candidate miRNAs can reduce the proinflammatory 
response of monocytes/macrophages and microglia, and these inhibitory effects of miRNAs are 
conserved during HIV-1 infection. In order to test this hypothesis, candidate miRNAs were over 
expressed in monocytic cell line (THP1) and microglia by using lentiviral expression vectors. 
Results suggest that miR-20a and miR-106b expression in monocytic cell lines inhibits TNF-α 
production, while miR-let-7a significantly downregulates IL-6 secretion in response to LPS either 
in the presence or absence of HIV-1 infection. Similarly, in microglia cells, miR-106b inhibits 
both IL-6 and IL-8 secretion upon LPS stimulation and miR-20a reduces IL-6 production upon 
TNF-α stimulation. Evaluation of these candidate miRNAs in J-Lat cells, which contain a single 
copy of HIV-1 latent HIV-1 virus suggest that, miR-20a, miR-106b, miR-124 and let-7a were 
able to reduce HIV-1 reactivation. These results indicate that neuroprotective miRNAs may have 
a direct role in reducing specific neuroinflammatory factor production and may also affect HIV-
1 virus production. Thus, these candidate miRNAs could have a potential therapeutic role to 
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The current global estimate for people living with HIV-1 (human immunodeficiency virus 
type 1) infection is 36.7 million (at the end of 2016) [1]. HIV-1 infection is a global public health 
concern, and various methods have been developed during the past 20 years to control this 
pandemic. Combination antiretroviral therapy (cART) has been very successful in controlling 
HIV-1 transmission and improving the quality of life of HIV-1 patients. This has led to a rapid 
decline in both incidence and mortality of HIV-1 infection [1]. Consequently, most of HIV-1 
positive patients currently are not suffering from acquired immunodeficiency syndrome (AIDS) 
but many of them are experiencing non-AIDS-related comorbidities including cardiovascular 
disease, bone loss and neurocognitive disorder [2]. Among those comorbidities, HIV-1 associated 
neurocognitive disorder (HAND) is observed in more than half of all HIV patients. Definitely, 
cART has helped to reduce the incidence of most severe form of HAND, HIV-1 associated 
dementia (HAD), but the milder form of HAND, has become more prevalent.  Currently, we do 
not have any specific therapeutics or treatment options to manage HAND. Thus, devising novel 
methods to manage HAND is of public health significance, especially, to improve the quality of 





1.1 HIV-1 PATHOLOGY 
 
 
1.1.1 HIV-1 structure and genome 
 
 
HIV-1 genome includes nine genes which are responsible for encoding 15 different HIV-1 
viral proteins (Figure 1) which are sufficient for HIV-1 virus to successfully establish an infection 
[3].  
 
Figure 1. Schematic of HIV-1 virus genomic organization. 
Thomas Splettstoesser, www.scistyle.com, 2014. 




HIV-1 genome includes two repeat sequences on either end known as Long Terminal 
Repeats (LTRs). LTRs serve as the promoter and enhancer of HIV-1 transcription and includes 
multiple binding sites for both host and viral factors. They regulate the expression of HIV-1 viral 
proteins encoded by the genome. 
Group associated antigen, also known as Gag, is the major structural protein of HIV virion. 
It has a molecular weight of 55 kilo Dalton (KDa) and is also identified as p55. During virus 
budding, Gag recruits two copies of the viral RNA and along with other structural proteins., It also  




3 proteins: Matrix (MA), Capsid (CA) and Nucleocapsid (NC). These 3 proteins are critical for 
protection of the viral RNA genome and essential for establishment of new infection [4]. 
Polymerase (Pol) is encoded by Pol gene. Pol is also a polyprotein which is processed to 
form 3 important enzymes: reverse transcriptase (RT), integrase (IN) and Protease (PR). RT is 
responsible for reverse transcription. IN is the viral enzyme that helps proviral cDNA to integrate 
into host genome, while protease has the ability to proteolytically cleave the viral pro-proteins at 
specific sites [5]. 
Envelope (Env) is vital to establish host cell infection. Host protease cleaves the viral pro-
protein to form two parts: the surface antigen (SU or gp120) which is able to bind to CD4 receptor 
and its co-receptor, CCR5 or CXCR4, to initiate membrane fusion by its conformational change. 
While the trans-membrane protein (TM or gp41) which aids in the process of fusion by sticking 
its fusion peptide in host membrane to complete the process of fusion [6, 7]. 
Rev is a viral regulatory protein which is able to bind to Rev Response Element (RRE) to 
export unspliced viral RNA out of nucleus. This is essential for retrovirus replication since 
unspliced RNA is unable to leave nucleus in eukaryotic cell [8]. 
Transactivator of Transcription, also known as Tat, is also a critical regulatory viral protein 
that enhances the transcriptional activity of HIV-1 LTR. In the absence of Tat, the activity of 
polymerase will be relatively weak and non-full length viral RNA transcripts will be synthesized 
[9]. 
Nef, Negative regulating factor, is also important in HIV-1 infection and viral pathogenesis. 
HIV-1 Nef is able to downregulate CD4 and MHC class I molecules on the surface of the infected 






Vpr, viral protein R, is another important accessory protein, which is essential for HIV-1 
virus to replicate in non-dividing cells like macrophages. Other functions of Vpr include inducing 
cell cycle arrest and nuclear import of pre-intergration complex [11, 12]. 
Vpu, viral protein U, is also an accessory protein and has an important role in the process 
of virion budding as well as CD4 degradation. HIV-1 Vif, Virus infectivity factor, also a viral 
accessory protein, is essential for degradation of host restriction factor, APOBEC proteins in non-
permissive cells including lymphocytes and macrophages [13, 14]. 
 
 
1.1.2 HIV-1 life cycle 
 
 
HIV-1 infection is a multistep process as pictured in figure 2 [15].  The first step of 
infection starts with a free viron attaching to the cell surface by the interaction of viral envelope 
glycoprotein gp120 with host CD4 receptor. Conformational changes occur in both gp120 and 
gp41 viral proteins following the initial interaction which allows former one to expose binding site 
to co-receptor CXCR4 or CCR5 (depend on the virus tropism) and the latter one to insert its fusion 
peptide into the host cellular membrane to complete the fusion of viral membrane with the host 
cytoplasmic membrane [16]. 
Following membrane fusion, the contents of the viron are released into the cytoplasm 
which eventually form a complex called preintegration complex (PIC). In the cytoplasm, the 
process of reverse transcription of viral RNA to cDNA is initiated by the reverse transcriptase. 
The newly formed proviral DNA together with the PIC move close to the nuclear pore complex 
then enter the nucleus via an active transport mechanism. Once the PIC enters nucleus, the 








Figure 2. HIV-1 Replication Cycle. 
Schematic diagram representing the entry, replication and release of HIV-1 virion from the target host cell. 





1.2 HIV-1 LATENCY IN CNS 
 
 
1.2.1 HIV-1 Persistence and therapeutic approaches 
 
 
cART has been highly successful in controlling virus replication and suppress the viral load 
in patients to undetectable levels, though complete elimination of HIV-1 infected cells is not 
currently possible. HIV-1 virus persists to remains transcriptionally silent for long duration only 
to re-emerge with the discontinuation of cART [19]. This latent reservoir is usually composed of 
resting CD4+ memory T cells residing in multiple places of human body [20]. In latent cells, the 




factor, for example, TNF-α or Tat, the LTRs in the provirus will be activated and start producing 
new virus particles resulting in productive infection. In addition, latency cells are typically long-
lived cells, making the latent reservoir extremely hard to be eradicated. According to a recent 
report, current cART drugs require 73.4 years to eradicate latent reservoir with an average half-
life of 44 months for the latent cells [21].  
Several therapeutic approaches are in development to control or eradicate the HIV-1 latent 
reservoir. The two major approaches include: sterilizing cure approach, which commits to 
completely eliminate all persistent HIV-1 virus. The second one is a functional cure, which tries 
to immunologically control the virus. The “shock and kill” strategy [22] is one of the sterilizing 
cure methods that currently under great interest. Briefly, this strategy tries to reactivate latent virus 
with drugs to produce virus leading to cytopathic killing and expose the latent virus containing 
cells to the immune surveillance and immune-mediated depletion of the latent cells. The normal 
uninfected cells are protected by cART during this process. However, recent studies have observed 
a high variation in the response of the latent virus pool to drugs[23]. 
Thus, in order to get better understanding of HIV-1 latency, in vitro latency models have 
been developed. Transformed Jurkat cells which is an immortalized human T lymphocyte cell line, 
have been used to study HIV-1 latency. J-Lat cell line contains latent form of HIV-1 virus that is 
envelope defective and the nef gene of this virus is replaced by an eGFP gene. Thus, when the 
provirus is reactivated by agents, such as Tumor Necrosis Factor alpha (TNFα) there will be GFP 
expression instead of nef expression. However, despite the advantage of genetic and experimental 
tractability of J-Lat cell, concerns have been raised for the relevance of this model to the actual 
settings in primary cells and limitations of this model including inherent mutations in proliferation 
cycles and clonal nature of virus integration sites [24]. Because of these concerns, the first primary 




latency models have been established with different virus vector in different phenotype of cells for 
the purpose to study multiple reactivators.  
 
1.2.2 Central Nervous System as Reservoir 
 
 
The central nervous system (CNS) is a unique anatomical compartment that is isolated from 
the rest of the human body by blood-brain barrier (BBB). BBB controls and limits the exchange 
of any substances between blood and brain. However, the BBB is not able to stop HIV-1 virus 
invading the CNS. HIV-1 virus enters CNS soon after acute infection via infected infiltrating 
monocytes/macrophages (ref). However, this unique structure is able to impede drugs and other 
immune cells, which makes CNS the potential reservoir for HIV-1 virus. Evidence that support 
this hypothesis include the presence of  integrated HIV-1 provirus in brain macrophages, 
microglia and astrocytes samples [26]. The long-lived and reduced immune surveillance nature of 
those local immune cells makes the CNS a perfect place for HIV-1 virus to hide. Also, 34% of 
subjects under cART treatment in one study have been found to have detectable level of HIV-1 
RNA in Cerebrospinal fluid (CSF) compared to a lower average detectable level of HIV-1 RNA 
in plasma, suggesting that CNS may have a higher reactivation activity than other parts of body 
[27]. Finally, the HIV-1 virus found in CNS are phylogenetically distinctive HIV-1 subtypes (YU-
2) which may limit the ability of latency reversing agents to facilitate “shock” and “kill” strategy 










1.3 MACROPHAGE AND HIV-1 ASSOCIATED NEUROCOGNITIVE DISORDER 
 
1.3.1 Role of macrophages in HIV-1 infection 
 
 
Macrophages are mononuclear leukocytes responsible for phagocytosis and antigen 
presentation. Macrophages reside in tissues of most part of the body post terminal differentiation 
[29]. Macrophages express CCR5 co-receptor and thus are capable of supporting HIV-1 infection. 
However, unlike CD4+ T cell, HIV-1 infection in macrophages does not cause any cytopathic or 
apoptotic effects, and this is likely due to the immune evasion effects of viral proteins. Viral 
proteins including Nef, Vpr and gp120 may all play a role in up-regulating NF-κB pathway to 
avoid TNF-α induced apoptosis in macrophages: soluble Nef can inhibit endosomal V-ATPase to 
up-regulate NF-κB pathway while Vpr may play a role in reducing TCR-mediated activation of 
NF-κB activity and last gp-120 may indirectly downregulate TNF-α ligand by increasing 
macrophage colony-stimulating factor (M-CSF) which is a pro-survival cytokine that modulates 
the differentiation of monocytes to reduce apoptosis [30-32]. Thus, under the effects of those viral 
proteins, macrophages are more likely to survive for long time with periodic viral replication and 
release rather than undergoing apoptosis. Together with the antigen presenting nature, 
macrophages are able to contribute to the viral susceptibility by continually presenting virus to 
CD4+ and CD8+ T cells and contribute to the permissiveness of HIV-1 virus by continuous 








1.3.2 Role of macrophage produced cytokines/chemokines in HIV-1 infection 
 
 
Cytokines are a broad category of small molecules (5–20 kDa) responsible for changing 
cell behavior in both the cells which release them and the cells nearby via autocrine and paracrine 
mechanisms. The cytokines work by binding to receptors on the cell surface, then the signal of 
cytokines are transduced to nucleus though signal transduction, resultin in modulation of specific 
gene transcription. While the chemokines are chemotactic cytokines which are able to use a 
concentration gradient to guide the migration of immune cell to the site of inflammation [33]. They 
are both important in immune responses and immune cell activation. However, under HIV-1 
infection, the virus manipulates cytokine production and immune activation to promote infection 
and viral replication. For example, TNF-α may facilitate HIV-1 replication by activating host NF-
κB pathway to further activate NF-κB binding sites in LTR of HIV-1 genome [34]. Similarly, 
interleukin 6 (IL-6), as a pro-inflammatory cytokine, has been reported to be a stimulatory cytokine 
that increases viral replication [35]. Also, interleukin-8 (IL-8), belongs to the C-X-C chemokine 
family, which is originally responsible for attracting neutrophils to fulfill monocyte adherence, has 
been shown to stimulate HIV-1 replication [36]. At last, chemokine (C-C motif) ligand 2 (CCL2) 
which helps to recruit memory T cells, monocytes and dendritic cells, is also believed to function 
on enhancing the HIV-1 infection. 
On the contrary, due to the existence of balance of cytokine network, some cytokines may 
also play an inhibitory role in viral replication to poise the effect of HIV-1 stimulatory cytokines. 
For instance, macrophage inflammatory protein 1α and 1β (MIP-1α, MIP-1β), can bind to the 
CCR5 receptor and thus block the entry of HIV-1 virons. And IL-10 is believed to constrain HIV-





1.3.3 Neuropathogenesis of HAND 
 
 
HIV-1 associated neurocognitive disorder (HAND) is one of the major HIV co-morbidities 
and the clinical manifestations of HAND are: loss of neuronal density with neuronal damage and 
loss of dendrities [39]. In the early stage of infection, HIV-1 infected monocytes/macrophages 
cross the BBB [40] which later enables infection of CNS resident monocytic cells and astrocytes 
(Figure 3). In the meantime, elevated production of TNF-α reduce the permeability of the BBB 
leading to further infiltrating of monocytes/macrophages [41]. Together with infected perivascular 
macrophages, microglia and astrocytes, host factor including pro-inflammatory cytokines and 
chemokines (e.g. TNF-α, IL-8, IL-1β, IL-6) are secreted, result in increased secretion of neurotoxic 
substances containing nitric oxide, platelet-activating factor (PAF) and quinolinic acid which stress 
the neurons. Finally, together with viral factors (Tat, Vpr, gp120), those neurotoxic factors lead to 
neuronal dysfunction and eventually to neuronal apoptosis [42].  
The damage of synapse may also in part responsible for the neuropathogenesis.. Normal 
synapse maintains physiological level of glutamate in the CNS, which is the major excitatory 
neurotransmitter to prevent toxic calcium influx in neurons. However, under HIV-1 infection, 
activated macrophages release excitotoxic glutamate mediated by the N-Methyl-D-aspartate 
(NMDA) receptor. Glutamate act in a paracrine way entering astrocytes and microglia where they 
disturb the normal maintenance of glutamate for neurons. Therefore, result in increasing uptake of 
calcium (Ca2+) in synapse which activate calcium-dependent proteases capable for disrupting the 
postsynaptic density (PSD). The disrupted PSD then leads to neurodegeneration and synapse 
disruption [43]. 
Another interpretation for HAND neuropathogenesis is the possibility of reduced 




neurogenesis (ANG) by impairing the proliferation and migration of immature neurons as well as 
expropriating the support from astrocytes for neurons. As a result, patients may suffer from loss of 
learning ability and anxiety-related behaviors which are the corresponsive clinical manifestations 





Figure 3. Macrophage-Microglia-Astrocytes-Neurons network: Role in HAND pathogenesis. 
HIV-1 virus mainly enters the CNS compartment through infected macrophages which recruit CNS resident microglia and can 
infect both microglia and astrocytes. Direct HIV-1 infection of neurons is not detected and the neurotoxic effects in HAND are 
due to viral proteins and the host factors, mainly the proinflammatory factors released by HIV-1 infected/ exposed 









1.4 ROLE OF MIRNA IN HAND 
 
 
1.4.1 MicroRNA (miRNA) biology 
 
 
MicroRNAs are 21-23 nt long, non-coding RNAs which have a role in post-transcriptional 
regulation by altering the stability of target mRNAs [46]. Pri-microRNAs are first transcribed by 
RNA polymerase II and later cleaved by RNAse III Drosha into pre-microRNA in nucleus [47]. 
Then the pre-microRNAs are transported out of the nucleus via Exportin 5. In cytoplasm, with the 
help of RNAse III Dicer, the pre-microRNAs lost their hairpin structure, forming duplex 
complementary structure. Only one strain of this dsRNA in the structure has the ability to become 
the mature microRNA and later this strain forms a RNA-induced silencing complex (RISC). This 
RISC then binds to the 3’ untranslated region (UTR) of target mRNAs which leads to degradation, 
repression or deadenylation of targeted mRNA. It is predicted that nearly more than 60% of protein 
coding mRNAs in human contain UTR region for miRNA to bind [48]. Thus, miRNAs play an 
important role in the regulation of all biological pathways including homeostasis of cellular 
interaction, cell proliferation and cell differentiation. In addition, studies have shown that one 




1.4.2 Host and viral miRNA 
 
 
Multiple studies have identified a functional role for miRNAs in cancer, for example, miR-




apoptotic protein enriched in malignant cells [50]. Similarly, many researchers also tried to identify 
the function of miRNAs in infectious disease also. During this process, many miRNAs have been 
found to correlate with HIV-1 infection. One study found that suppression of miRNA-28, miRNA-
150, miRNA-223 and miRNA-382 in monocytes increase HIV-1 infectivity while escalate of those 
anti–HIV-1 miRNAs in macrophages inhibited HIV-1 replication [51]. MiRNA-221 and miRNA-
222 were also found to inhibit HIV-1 entry in macrophages by affecting the CD4 receptor [52] and 
miR-29a has been shown to target HIV-1 Nef transcription in CD4+ T cells [53]. Thus, these 
findings implicate that anti–HIV-1 miRNAs may have a key role in protecting immune cells from 
HIV-1 infection. 
On the contrary, miRNAs can also be encoded by many viruses, including HIV-1. HIV-1 
encodes microRNAs intending to suppress immune system and thus create a favorable 
environment for viral invasion and replication. As we mentioned above, HIV-1 transactivation 
response element (TAR) on LTR has the function on initiating transactivation. Recently studies 
have also found that TAR region may also act as the source of viral miRNAs [54].  HIV-1 miR-
TAR-3p and HIV-1 miR-TAR-5p are two viral miRNAs which were found to target cellular 
apoptotic factors and proliferation regulators, respectively, to promote viral latency [55]. HIV-1 
miR-N367 which derived from Nef gene was reported to control viral transcriptional factors and 
regulators through negative responsive element in the 5'-LTR to suppress HIV-1 replication [56]. 
 
 
1.4.3 Neuroprotective role of miRNA 
 
The role of miRNAs in the pathogenesis of HAND is an area of interest. Multiple studies 




[57]. But how these miRNAs protect neuronal function in HAND remains unclear. There are two 
hypotheses to explain the function of neuroprotective miRNAs: First, miRNAs may have a direct 
role in protecting neurons. Many studies have shown the function of miRNAs in neuronal recovery 
after ALS progression and neuron ischemia [58, 59], indicating that a similar mechanism may also 
exist in the case of HAND. In addition, the miRNAs which have direct role in protecting neurons 
may also be able to travel from glial cells to neurons by exosomes. For example, miR-26a which 
derived from astrocytes is reported to potentially increase the neuronal plasticity which is the 
hallmark of neuronal health [60]. 
The other hypothesis focuses on the function of miRNAs affecting cytokines received by 
neurons. Infected neuronal support cells may release large volume of cytokines which stress 
neurons. In this situation, miRNAs in neuronal support cells which are able to control the cytokine 
production should also be considered as neuroprotective. As two important neuronal support cells, 
specific miRNAs in astrocyte and microglia were found to reduce pro-inflammatory cytokine 
production [61, 62]. However, as we mentioned above, HIV-1 virus initiates CNS infection 
through infiltrating monocytes/macrophages, which further infects local glial cells and amplify the 
cytokine storm in the brain. Thus, if we are able to control the scale of the cytokines, the protective 
role of miRNAs may become more effective. For this reason, we overexpressed candidate miRNAs 
in monocytes/macrophages to study their effects on cytokine production. 
 
 
1.4.4 Identification of candidate miRNAs 
 
Candidate microRNAs- miR-let-7a, miR-124, miR-20a and miR-106b were identified by 
comparing miRNA and mRNA profiles between HIV-1 positive patients with or without HAND 




published paper of our lab [57]. Briefly, total PBMCs from HIV-1 seronegative individuals and 
HIV-1 seropositive individuals without neurocognitive symptoms, or with MND or HAD were 
systematic evaluated for of global transcriptome. Candidate miRNAs were upregulated in HAND 
resistant HIV-1 patients and were predicted to be upstream regulators in HAND. MiR-let-7a and 
miR-124 were predicted to target chemokine signaling especially for IL-8, CCL2 and CXCR4 
through RHOG, JUN, MAPK3 and RAF1 signal transduction process. While miR-20a and miR-
106b were predicted to target cytokines including TNF-α, IL1β and IL-6 through DUSP2, 
NOTCH1 and FOXO1 signal transduction process. Thus, candidate miRNAs could potentially 
have a neuron-protective role by inhibiting chemotaxis of inflammatory immune cells in CNS and 







2.0  AIMS OF THE PROJECT 
 
 
The following specific aims focus to evaluate the role of miRNAs to combat HAND 
Aim 1: Investigate the role of candidate miRNAs to alter neuroinflammatory 
chemokines/ cytokines and surface receptor expression in miRNA transduced monocytes 
and microglia cells.  
A. Development of specific miRNA expressing monocytes and microglia 
using lentiviral expression vectors. 
B. Confirm transduction efficiency and candidiate miRNA expression using 
flow cytometry and q-RT PCR.  
C. Evaluate changes in surface receptor expression in transduced monocytes. 
D. Verify changes in specific cytokine/chemokines in miRNA transduced 
monocytes. 
E. Analyze the role of exosomes in miRNA mediated effects. 
F. Verify changes in specific cytokine/chemokine in miRNAs transduced 
microglia. 
 
Aim 2: Investigate the ability of these miRNA expressing monocytes/macrophages to 
reactivate latent HIV-1 using HIV-1 reporter latent cell line. 
 
A. Evaluate the role of miRNA transduced cell lines to reactivate latent HIV-
1 virus in J-lat cells. 
B. Investigate the host cellular factors responsible for reactivation of latent 












HEK-293T and microglia cells were maintained at 37°C, 5% CO2 in DMEM (Gibco) 
which contains 10% fetal bovine serum (HyClone), 1% L-glutamine (Invitrogen), and 1% 
streptomycin (Invitrogen). THP1 cells were similarly maintained in RPMI with 10% fetal bovine 
serum, 1% L-glutamine, and 1% streptomycin. 
 
3.1.2 Construction of miRNA vector 
Lentivirus vectors expressing specific miRNA were obtained from GeneCopoeiaTM. Figure 
4 is an example of hsa-let-7a-1 miRNA vector. The characteristics of this vector include a 
backbone based on pEZX-MR03 (HIV-based) vector, a 5’ LTR with packaging elements and a 3’-
LTR with poly A. It also includes a CMV promotor and Puromycin stable selection marker. The 



















Figure 4. Schematic denoting the structure of miRNA expression vector.  
The miRNA expression is on a lentivirus backbone with an internal CMV promoter that drives the expression of 
eGFP and miRNA as a fusion transcript. The lentivirus also includes puromycin resistance gene for selection 
against puromycin antibiotic. 
 
 
3.1.3 Lentivirus production and Transduction of Target Cells 
 
HEK-293T cells were trypsined by 0.25% of 1X Trypsin-EDTA (gibco) then seeded in 10 
cm2 tissue culture-grade plates, which were then grown overnight until the HEK 293T cells 
becoming adherent and reaching 80% of confluence.  
Two and half (2.5) μg miRNA expression vector was mixed with 0.5μg of PLP1 which 
stands for packaging plasmids containing gag and pol, and 0.5μg of Vpx expressing plasmid 
(which functions on degradation of SamHD1 in monocytes) and 0.5μg of PLP2 (provide Rev gene) 
and pVSV-G-Env of vesicular stomatitis virus (VSV), respectively, in 250μl of DMEM. Then 15μl 
of PolyjetTM transfection reagent was mixed with 250ul of fresh DMEM first then added to the 
plasmid mixture. After 15 minutes of incubation, the whole mixture was added drop-wise to the 




After 24 hours of incubation, 5ml of fresh media was added to the plate to maintain the 
cells. 48 hours post-transfection, the supernatant was harvested and purified using a 0.22µm filter 
unit (Steriflip®). Virus titer was then quantified by a TZM-bl assay using 1:10, 1:100, 1:1000 and 
undiluted quantities of virus to infect 4.0 x 104 TZM-bl cells with an incubation period of 6 hours. 
After 6 hours, the media was changed with fresh media and the plate was incubated for another 48 
hours. TZM-bl cells were stained with β- galactosidase substrate for 4 hours and counted in the 
optimal well to measure infectious particles. 
Virus of 0.1 and 1 MOI from the HEK 293T supernatant were added to the washed THP1 
cells or microglia cells for transduction and incubated for 24 hours before replacing the cells with 
fresh media. 72 hours post-transduction, 1μg /ml of puromycin was added to the media to select 
transduced cells.  
 
 
3.1.4 Total RNA extraction and cDNA preparation 
 
Total RNA was extracted using mirVanaTM miRNA isolation kit as described by the 
manufacturer. Briefly, cell pellets of miRNA-transduced THP1 cell line were collected by 1000 
rpm spinning. 1x106 cells were washed with PBS then lysed in 600 μl of Lysis/Binding Solution. 
50 μl of miRNA Homogenate Additive was added to the lysed solution with a 30 seconds vortex 
for mixing. The mixture solution was then left on ice for 10 minutes incubation. 500 μl of 
AcidPhenol: Chloroform was added to the solution after the incubation with a 30 seconds intense 




After the centrifugation, the upper aqueous layer was carefully transferred to a microcentrifuge 
tube. Next, one volume of 100% ethanol was added to the microcentrifuge tube then the whole 
mixture was passed through a RNA binding filter with a short 10,000g centrifugation. Similarly, 
one time of 700 μl of miRNA Wash Solution 1 and twice of miRNA Wash Solution 2/3 were 
passed through the filter to clean the RNA on the membrane. After three times of wash, the empty 
filter cartridge was centrifuged for 30 seconds for removing residual fluid. Then the membrane 
was transferred to a new collection tube. 100 μl of the heated Elution Solution (95°C) was added 
to the central of the filter with a 30 seconds centrifugation to get RNA sample. Finally, the 




Figure 5. cDNA synthesis for miRNA quantitation.  





cDNA reverse transcription was performed using All-in-OneTM miRNA qRT-PCR 
Detection Kit (GeneCopoeia) including total RNA obtained from transduced THP1 cell lines. 
Since miRNA are relatively very short to be detected by regular qRT-pCR, Poly-A tails were added 
to the 3’ end of miRNA before reverse transcription (Figure 5). Following the steps in Table 1, all 
the reagents were mixed to a final volume of 25 µl. Next, the mixture was incubated at 37°C for 
60 minutes for addition of Poly(A) tails by Poly(A) Polymerse following another incubation at 
85°C for 5 minutes to inactivate the enzyme. Finally, the cDNA products were ready for next 
qPCR experiment or it can be stored at –20°C, using specific primers. 
 
Table 1. Reactants for cDNA reverse transcription 
 
Reagent Volume Quantity 




RTase Mix 1µl  
5xPAP/RT Buffer 5µl 1x 








All-in-OneTM miRNA qRT-PCR Detection Kit (GeneCopoeia) and All-in-OneTM miRNA 
qPCR primer designed for candidate miRNA were used in this process. cDNA generated above 
22  
was diluted to 50 times with sterile H2O before performing qPCR. qPCR mixture was prepared 
according to table 2 in triplicates, then the samples were run in the ABI Prism 7000 Sequence 
detection system as per the conditions described in Table 3 In this analysis, the ΔΔCT method was 
used to generate relative expression and U6 small RNA was included as the endogenous control. 
 
Table 2. Real Time PCR reactants per reaction for miRNA detection 
 
Reagent Volume Concentration 
2×All-in-One qPCR Mix 10 µl 1× 
All-in-One TM miRNA 
qPCR Primer (2 µM) 
2 µl 0.2 µM 
Universal Adaptor PCR 
Primer (2 µM) 
2 µl 0.2 µM 
First-strand cDNA 
(diluted 1:5) 
2 µl  






Table 3. Running condition for detection of miRNA 
 
Cycles Steps Temperature Time 
1 Initial 
denaturation 
95°C 10 min 
 
40 
Denaturation 95°C 10 sec 
2 µl 62°C 20 sec 




3.1.6 Intracellular staining and flow cytometry 
 
 
Intracellular staining of cytokines followed by flow cytometry was used to evaluate the 
amount of cytokines expressed at single cell level. Intracellular cytokine staining was carried out 
following the standard staining protocol. Cells (1 × 106) at the mentioned time point were 
stimulated with LPS (1 µg/ml) in the presence of GolgiStop (2 μl/ml) for a duration of 4 h. 
Intracellular staining was done with 5 µl PE cy7 anti-human TNF-α antibody (eBioscience), 5 µl 
APC anti-human IL-6 antibody (BioLegend), and 20 µl Pacific BlueTM anti-human IL-8 antibody 
(BioLegend). The cells were then washed twice with 1X Perm/Wash buffer and kept in FACS 
buffer with 1% paraformaldehyde. Flow cytometry analysis was performed on these cells with the 
LSRFortessaTM cell analyzer (BD Biosciences) and FACSDiva® software (BD Biosciences).  
 
3.1.7 Cytokine ELISA quantification 
 
 
Following infection with HIV-1 or mock infection, cells were treated with LPS (1µg/ml) 
for 24 hours and the supernatants were collected and analyzed for the presence of IL-8, TNF-α, 
CCL2, and IL-6. Human IL-8 DuoSet ELISA kit (R&D Systems), Human TNF-α DuoSet ELISA 
kit (R&D Systems), Human CCL2 DuoSet ELISA kit (R&D Systems) and Human IL-6 DuoSet 
ELISA kit (R&D Systems) were used for the ELISA analysis. 100 µl of 1:60 PBS diluted different 
capture antibodies were added to a 96-well plate then incubated overnight at 4℃. Next day, the 




blocking buffer (1% BSA in PBS) was added to each well with 1hour incubation period at room 
temperature. After blocking, plates were washed and, dried thoroughly.  
Harvested supernatants were diluted to an appropriate concentration and then 100µl of each 
sample was add to each well containing different ELISA capture antibodies. At same time, an  
eight-point 2-fold serial dilutions for each cytokine standard was made and added to the 
plate with the highest standard concentration, 1000pg/ml. All the samples and standards were 
incubated at room temperature for 2 hours. 
After 2 hours, the plate was washed three times as before, and 100µl detection antibody for 
each cytokine was diluted to 100 ng/ml in reagent diluent (1% BSA in PBS) then added to each 
well with an incubation period of 2 hours at room temperature. 
After 2 hours, the plate was washed three times and Streptavidin conjugated to horseradish-
peroxidase (HRP) was then diluted to 1:40 fold in reagent diluent and 100µl was added to each well 
for 20 minutes. 
Tetramethylbenzidine (TMB) substrate (BD OptEIATM) was used for detection. Equal 
amounts (50µl) of Substrate Reagent A and Substrate Reagent B were added to each well then 
incubated for another 20 minutes in dark. 
One hundred (100) µl of 2 N H2SO4 was then added to stop the reaction and the color 
intensity was read by ELx800 Absorbance Microplate Reader (Bio-Tek) with KCJuniorTM software 
(Bio-Tek). Linear trend lines were created from the standard curves with known concentrations and 






3.1.8 Total Exosome Isolation 
 
 
Total exosomes were isolated from the cell supernatant using Total Exosome Isolation 
Reagent (Invitrogen). Exosomes are small vesicles containing miRNA, cytokines and other 
signaling molecules which secreted by cells as intercellular messenger. Transduced THP1 cells 
were cultured in FBS free RPMI media for 24 hours and stimulated with 1µg/ml LPS stimulation. 
Then 1ml of cell-free culture media was harvested and transferred to a new tube and 500 µl of 
Total Exosome Isolation reagent was added to the same tube following an overnight incubation at 
4℃. Next day, the sample was centrifuged at 10,000 × g for 1 hour at 4℃ to isolate the exosomes. 
Then the exosome pellet was resuspended in 200µl 1X PBS for further analysis. 
 
3.1.9 Statistical Analysis 
 
The results are expressed as mean ± standard deviation. The data were analyzed using the 
















4.1. AIM 1: INVESTIGATE THE ROLE OF CANDIDATE MIRNAS TO ALTER 
NEUROINFLAMMATORY CHEMOKINES/ CYTOKINES AND SURFACE 
RECEPTOR EXPRESSION IN MIRNA TRANSDUCED MONOCYTIC CELL 
LINE AND MICROGLIA 
 
 
4.1.1 Expression of candidate miRNAs in monocytic cell line, THP1 
 
 
Monocytic cell line, THP1, was transduced with lentivirus vector expressing miRNA. The 
eGFP coding mRNA transcripts and miRNA transcripts are driven by the same CMV promoter, 
the eGFP reporter expression reflects the transduction efficiency of the lentivirus and indirectly 
also reflects the miRNA expression. The percentage of eGFP positive cells for individual candidate 
miRNA expressing cell line were estimated by flow cytometry. As represented in Figure 6A, after 
selection with puromycin, more than 90% of the cells express miR-20a, miR-106b, miR-124 and 
miR-scramble based oneGFP expression, while less than 1% of auto-fluorescence was observed 
in untransduced THP1 cells and 80% of cells expressing miR-let-7a were eGFP positive. 
Interestingly, the resistance of these cell lines to puromycin was different. THP1 cells expressing 
miR-20a, miR-106b and miR-124 were highly resistant to puromycin selection and the eGFP 





THP1 cell lines were only able to tolerate  0.5µg/ml of puromycin which may explain the 








Figure 6. Expression of candidate miRNAs in THP1 cell line. 
MiRNA transduced THP1 cell lines were selected using puromycin. Then miRNA expression in each cell 
lines were confirmed by evaluating eGFP expression using flow cytometry and qRT-PCR. A. The 
untransduced THP1 cells are used as control for determining the cut-off. B. Amplification plot data of a 
representative miR-124 quantitation. C. Fold change were estimated using the ∆∆Ct method relative to 







Next, the expression of candidate miRNA in the THP1 cell line were confirmed by qRT-
PCR including specific primers. Total RNA was extracted from the transduced THP1 cell lines 
was included in the cDNA reaction. Before converting to cDNA, Poly-A tails were added to the 3’ 
end of miRNA using Poly-A Polymerse. U6 small nuclear RNA was included for normalization 
and the expression of the candidate miRNAs in the transduced cells lines relative to untransduced 
THP1 cells were estimated by ΔΔCT method. In Figure 6B, a representative amplification plot 
of miR-124 is included to demonstrate the increased level of miRNA expression in miRNA 
transduced monocytes compared to untransduced THP1 cells. Results suggest that the candidate 
miRNA expressing cell lines have 100-400 fold increase in expression of specific miRNAs (Figure 
6C). However, we were unable to detect the expression of scramble miRNA. There is no 
endogenous expression of scramble miRNA in untransduced THP1 cells and the inability to detect 
in the lentivirus transduced cell line suggests the possibility of mismatch in primer or probe binding 
region. These results from flow cytometry and qRT-PCR, suggest that lentivirus transduced THP1 




4.1.2 Effects of candidate miRNAs on cytokine production in monocytic cell line 
 
 
Previous published results from our lab and others suggest that the candidate miRNAs 
might potentially target inflammatory cytokines [57]. Here, we evaluated the ability of THP1 




receptor, and the downstream signaling induces a strong proinflammtory response in human 
monocytes and macrophages with production of TNF-α, IL-1β, IL-6 and IL-8. THP1 cells were 
stimulated with LPS (1µg/ml) for 4 hours in the presence of GolgiPlug, which is a protein transport 
inhibitor that retains newly synthesized cytokines in the ER. Intracellular staining of TNF-α and 
IL-8 were performed followed by flow cytometry analysis. The percentage of cytokine positive 
cells in the eGFP positive cells were determined. Results suggest that 87.5% of the cells were 
positive for TNF-α in the THP1 cells expressing scramble miRNAs while, miR-20a and miR-106b 
reduced TNF-α cytokine-positive cells to 0.94% and 5.27%, respectively (Figure 7A). There was 
no significant decrease in the percentage of cells expressing TNF-α, in miR-124 or let-7a 
expressing cells. Similarly, in Figure 7B, miR-106b expressing cell line showed a significant 
decrease in the number of IL-8 positive cells (1.1%) in comparison to miR-Scramble (11.1%). 
However, more than 35% of eGFP negative cells were observed in the miR-Scramble, miR-20a, 
miR-124 and miR-let-7a expressing cell lines in the cytokine flow cytometry analysis of IL-8 but 
not seen in the TNF-α group. However, this was not corresponding to the results in Figure 6 where 
more than 95% of the cells were miRNA expressing cells. This is likely due to over-








Figure 7. Effects of candidate miRNAs on intracellular cytokine production.  
MiRNA transduced THP1 cell lines were stimulated with 1µg/ml LPS for 4 hours in the presence of 




Figure 8. Effects of candidate miRNAs on surface receptor TLR-4 expression. 
Cells were stained with specific antibody to detect surface expression of TLR4 and the expression was 
estimated by flow cytometry. 
 
 
Considering the multi-target function of miRNAs and the complexity of signal 
transduction, the TLR-4 receptor may also be targeted by our candidate miRNAs, predictive 




cytokines by miRNAs may actually result from the loss of TLR4 receptors and their inability to 
bind to LPS. To evaluate this, the surface expression of TLR4 was evaluated by staining with 
specific antibody and flow cytometry. Results (Figure 8), suggest that none of candidate miRNAs 
directly target TLR4 receptor. These results suggest that the ability of miRNA to target cytokine 
secretion is independent of TLR4 expression. 
 
 
4.1.3 Expression of cytokines in miRNAs expressing monocytes during HIV-1 infection 
 
 
Results from intracellular cytokine evaluation suggests that miR-20a and miR-106b reduce 
TNF-α production in THP1 cells and miR-106b was also able to inhibit IL-8 production in these 
cells. Next, to confirm the effect of candidate miRNAs on cytokines secreted in the supernatant, 
especially at later time points, the miRNA expressing THP1 cells were similarly stimulated with 
1µg/ml LPS and the cytokines released in the supernatant were estimated by ELISA. As shown in 
Figure 9A, we observed that miR-20a and miR-106b can inhibit TNF-α when stimulated with LPS. 
The TNF-α released in the supernatant by THP1 cells expressing miR-20a and miR-106b in 
response to LPS was ~ 4.4 ng/ml, while THP1 cells expressing scramble control had TNF-α of ~ 
32.5 ng/ml. miR-124 also demonstrated a relatively small but significant inhibition of TNF-α 
production. Interestingly, unlike the results in intracellular staining for IL-8, none of our candidate 
miRNAs were able to significantly affect the IL-8 production in the supernatant as shown in Figure 
9C. This is likely due to difference in the time kinetics of cytokines produced in 4 hours versus 24 




that miR-20a reduced IL-6 and CCL2 that was minimal and was not significant. THP1 cells 
expressing miR-106b had IL-6 and CCL2 levels similar to scramble control. However, THP1 cells 
expressing miR-let-7a significantly inhibited IL-6 and CCL2 production in the supernatant, as 
predicted by the miRNA-cytokine regulation network. The IL-6 and CCL2 produced by miR-let-
7a expressing THP1 in response to LPS were 8.7 ng/ml and 1874 ng/ml, in comparison to 7,214 






Figure 9. Cytokines production of miRNA expressing monocytes by LPS stimulation in the presence of NL-
YU2 virus. 
Amount of cytokine secreted were quantified by ELISA for A. TNF-α, B. IL-6, C. IL8 and D. CCL2. in 
supernatants obtained from THP1 cells stimulated with 1µg/ml LPS only (left) for 48 hours plus infection 
with NL-YU2 virus (right). All the supernatants were harvested after 24 hours post LPS simulation. Figures 






Next, I evaluated the effects of miRNA in the context of HIV-1 infection, miRNA 
transduced THP1 cells were infected with 1 MOI of HIV-1 NL-YU2 virus. NL-YU2 virus is a 
neurotrophic HIV-1 strain isolated from CNS compartment. Forty-eight hours post-infection, the 
cells were treated with 1µg/ml LPS and the supernatant were collected at 24 hours post stimulation 
for ELISA analysis. Results suggest that during HIV-1 infection, cytokines were upregulated when 
compared to uninfected group, especially IL-8 (Figure 9C). As expected, in Figure 9A, we 
observed a similar patterns of inhibition of specific cytokines by candidate miRNAs, where miR-
20a, miR-106b and miR-124 were able to significantly inhibit TNF-α production, and miR-let-7a 
was able to inhibit IL-6 and CCL2 production even during HIV-1 infection (Figure 9B and 9D). 
These results suggest that the candidate miRNAs also inhibit specific cytokine production even in 
the presence of HIV-1infection in monocytic cell line, THP1. Thus, as previously discussed in 
section 1.3.1, HIV-1 virus can regulate cytokine production to promote infection and viral 
replication, which may contribute to the elevated level of cytokines during HIV-1 infection. 
Together, the results suggest that candidate miRNAs have a role in regulating cytokines and may 
contribute to neuroprotection during HAND pathogenesis. 
 
4.1.4 Expression of cytokines in miRNAs expressing microglia during HIV-1 infection 
 
 
As previously discussed in section 1.3.1, microglia have a critical role in HAND 
pathogenesis, and amplify the inflammation of HIV-1 infected macrophages. Microglia also serves 




Microglia-Astrocyte-Neurons Network. Next, I investigated the role of miRNAs in microglia. 
Experimental design and methodology to evaluate the role of candidate miRNAs in microglia were 
similar to the experiments performed with THP1 cells. Briefly, miRNA transduced microglia were 
stimulated with LPS or TNF-α and the supernatant were collected at 24 hours post-stimulation. 
Also the changes in cytokine production in response to HIV-1 infection was evaluated. TNF-α was 
included as an activator in the experiments, since TNF-α is a major cytokine released by 
infiltrating infected macrophages which can directly activate local CNS resident microglia during 
HAND neuropathogenesis. Also 10 µg/ml of LPS was used instead of 1 µg/ml LPS since microglia 










Figure 10. Cytokines production in miRNA expressing microglia stimulated with (A) TNF-a (B) LPS (C) HIV-
1 (NL-YU2) infection. 
Amount of cytokine secretion in the supernatant were estimated by ELISA (in pg/ml) following stimulation 
with different stimulators: A. TNF-α, B. LPS, C. NL-YU2 virus. The level of IL-8 secretion was shown on 
left and IL-6 was shown on right. All the supernatants were harvested after 24 hours of simulation. Error bars 






As shown in Figure 10A, we observed that miR-20a and miR-106b significantly inhibited 
IL-6 production in response to 1 µg/ml of TNF-α. IL-6 released in the supernatant by microglia 
expressing miR-20a and miR-106b wase 2,040 pg/ml and 2,654 pg/ml, in comparison to an 
average of 4,380 pg/ml in microglia expressing scramble miRNA. However, no significant 
inhibition was observed in the production of IL-8 with TNF-α stimulation in the candidate miRNA 
expressing microglia. 
As shown in Figure 10B, IL-8 produced by microglia that expressing miR-20a and miR-
106b was half in comparison to the average of 58,000 pg/ml in Scramble miRNA expressing cells. 
Evaluation of IL-6 in these microglia cells suggests that miR-20a reduced IL-6 from 36,420 pg/ml 
to 18,320 pg/ml. Interestingly, in monocytes, miR-let-7a was able to reduce IL-6 to a low level 
compare to scramble but none of miR-20a or miR-106b have shown the ability of IL-8 inhibition. 
This is likely due to difference in expression of miRNA target transcripts/ protein and the presence 
of alternate pathways of signal transduction. Results also suggest that certain miRNAs may have 
a variable response with different stimulators. miR-20a and 106b inhibited IL-8 production, when 
stimulated by LPS but not with TNF-α; similarly, miR-20a and miR-106b inhibited IL-6 only when 
stimulated with TNF-α but not with LPS. 
Next, to evaluate the effect of HIV-1 infection, miRNA transduced microglia were infected 
with 1 MOI HIV-1 NL-YU-2 virus.  MiR-20a and miR-106b expressing microglia were able to 
inhibit IL-8 production from the average of 27,300 pg/ml to an average of 14,324 pg/ml and 10,320 
pg/ml, respectively, in comparison to Scramble miRNA (Figure 10C). While the evaluation of IL-




reduce production of cytokines during HIV-1 infection. LPS stimulation was not included post 
HIV-1 (NL-YU-2) infection for microglia since the infection of virus alone stimulated the 
microglia to produce up to 46,200 pg/ml of IL-8 and 57,800 pg/ml of IL-6 which is comparable to 
stimulators.  
Together, the results in miRNA-transduced microglia further support the hypothesis that 
the candidate miRNAs have a role in regulating cytokine production in microglia and monocytes 




4.1.5 Role of Exosomes derived from miRNAs Expressing Monocytes 
 
 
Exosomes are small vesicles that act as intercellular messengers for transmission of 
signaling molecules including cytokines and miRNAs. Thus, exosome may serve as an importance 
factor in HAND neuropathogenesis. Hence we evaluated the amount of cytokines present in the 
exosomes and the presence of miRNAs in the exosomes.  The amount of cytokine presents in the 
supernatant harvested from monocytes (FBS-free culture media) and exosome isolated from the 
same supernatant was evaluated by ELISA. As shown in figure 11A, exosomes derived from miR-
20a, miR-106b and miR-let-7a expressing monocytes showed a reduction of IL-6 to 23 pg/ml, 35 
pg/ml and 125 pg/ml, respectively, in comparison to 528 pg/ml in Scramble. While similar patterns 
were observed with the level of IL-8 in exosomes, where we observed that miR-20a, miR-106b 




corresponding supernatant suggest that (Figure 11B), only miR-let-7a and miR-106b inhibited IL-
6 and IL-8 production, respectively. This divergence between cytokine in exosomes and 
supernatant can be due to differences in the time kinetics of cytokine secretion, where the cytokine 
presents in the exosome represent recent production of cytokine versus the presence of cytokine 
in the supernatant is the result of accumulation of cytokine released over the entire experimental 
period (24 hours).  
Exosome may also contain miRNAs that can be directly delivered to bystander cells and 
can be functional. During HAND, miRNA over expressing monocytes or microglia could also have 
a neuroprotective role by deliveringprotective miRNAs to neurons and other neuronal support 
cells, such as astrocytes. Thus, a real-time PCR based evaluation was performed to detect the 
presence of miRNAs in exosomes derived from miRNA overexpressing monocyticcell lines. 
However, none of the candidate miRNAs were detected in exosomes. This can be due to limit of 









Figure 11. Amount of cytokines in exosomes versus supernatant. 
Cytokine production level were estimated by ELISA (in pg/ml) in A. Exosome and B. supernatant. The level 
of IL-6 secretion is shown on left and IL-8 is shown on right. The exosomes were extracted from the 








4.2 AIM 2: INVESTIGATE THE ABILITY OF THESE MIRNA EXPRESSING 
MONOCYTES TO ACTIVATE LATENT HIV-1 VIRUS USING LATENT HIV-1 
REPORTER CELL LINE 
 
In the previous aim, I evaluated the role of candidate miRNAs in regulating 
neuroinflammatory chemokines/cytokines production in monocytes and microglia. Next, I 
evaluated if these miRNAs can affect HIV-1 infection. CNS is a potential reservoir for latent HIV-
1 virus and CNS viral reactivation can potentially contribute to neuronal toxicity due to the 
production of viral toxic factors. Thus, investigating the ability of candidate miRNAs to affect 
virus reactivation and replication is also important.  
 
4.2.1 Characterization of HIV-1 latent reporter cell line by cytokine stimulation 
 
 
J-Lat cells are derived from Jurkat-based T cell line that harbor an integrated HIV-1 
replication defective eGFP reporter virus. The virus does not express HIV-1 envelope and the open 
reading frame of Nef is interrupted by eGFP gene. The virus in this cell line is latent under normal 
condition and upon activation results in expression of eGFP reporter. To characterize the ability 
of cytokines to reactivate the latent virus, 1x106 J-Lat cells were treated with 2-fold serial dilutions 
of recombinant human TNF-α, IL-6, IL8 and CCL2 proteins, respectively and evaluated for the 
presence of eGFP by flow cytometry. As shown in the Figure 12A, the reactivation of latent HIV-
1 virus in J-Lat cell follows a dose dependent response with increasing concentration of TNF-α. 




virus in these cells and are similar to background expression of eGFP. Thus, these results suggest 
that TNF-α reactivates latent reporter HIV-1 virus in J-Lat cells but not other cytokines included 






Figure 12. Reactivation of latent HIV-1 in J-lat cells using human cytokines and chemokines. 
J-Lat cells were incubated with different concentration (2 fold serial dilution) of human cytokines and 
chemokines – TNF-α, IL-6, IL8 and CCL2 proteins start from 1000ng/ml. The reactivation of latent HIV-1 
virus in J-lat cells were estimated by evaluation of eGFP expression by flow cytometry. Representative data 
for A. TNF-α and B. IL-6 are included.  
 
 




Cells harboring latent HIV-1 virus are potentially present in the CNS compartment and the brain-
resident memory T cells (bTRM) could also play a role in latent HIV-1 reactivation related to neuronal 
injury. Thus, investigating the role of monocytes/macrophages in HIV-1 latency regulation in T 




evaluate the role of miRNA in monocyte/macrophage-mediated effect on HIV-1 latency, 0.1 
million J-Lat cells were treated with the supernatant derived from 1µg/ml LPS stimulated miRNA 
expressing monocytes for 24 hours and the eGFP expression was evaluated by flow cytometry. As 
shown in Figure 13, J-lat cells that were treated with supernatant from LPS-stimulated miR-20a 
and miR-106b expressing monocytes showed ~ 10% eGFP (latent HIV-1 reactivation), in 
comparison to Scramble which was considered as 100%. While J-lat cells treated with supernatant 
from LPS-stimulated miR-124 and miR-let-7a expressing monocytes also exhibited more than 50% 
of reduction in latent HIV-1 reactivation. These results suggest that miRNAs might have an 




Figure 13. Reactivation of latent HIV-1 in J-lat cells using supernatant from monocytes. 
Supernatant from THP1 cells stimulated with 1µg/ml LPS were collected 24 hours post stimulation and 
incubated with J-lat cells for 24 hours. The reactivation of latent HIV-1 virus in J-lat cells were estimated by 
evaluation of eGFP expression by flow cytometry. All the values were normalized to scramble, which is 













HIV infection in monocytes/macrophages plays an essential role in the establishment of 
CNS infection. As we previously discussed, infected monocytes/macrophages cross the blood-
brain-barrier and initiate local infection of resident monocytic cells and astrocytes. Through the 
Macrophage-Microglia-Astrocytes-Neurons network, proinflammatory cytokines and viral 
proteins secreted by infected immune and neuronal support cells in CNS act as neurotoxins to 
induce neuronal stress, leading to neuronal dysfunction and subsequently HAND. Multiple studies 
have observed changes in cytokine profiles during HIV-1 infection of CNS [63, 64] and studies in 
our lab have demonstrated the differences in miRNA expression during HAND progression [57]. 
Thus, it will be interesting to verify if miRNA expression is correlated with the changes in cytokine 
profile and if the identified miRNAs play a role in the regulation of cytokine in CNS. 
In our previous studies [57], computational methods predicted that miR-let-7a, miR-124, 
miR-20a and miR-106b to be the upstream regulators of cellular factors involved in development 
of HAND. MiR-let-7a and miR-124 were predicted to target chemokine signaling specifically 
related to IL-8, CCL2 and CXCR4 through RHOG, JUN, MAPK3 and RAF1 and thus could 
potentially have a neuron-protective role by inhibiting chemotaxis of inflammatory immune cells 
and reducing associated pro-inflammatory response. While miR-20a and miR-106b, which share 
seed sequence with miR-17-5p, were predicted to target cytokines including TNF-α, IL1β and IL-




published studies have identified a role of candidate miRNAs in cytokines regulation. For example, 
one study demonstrated that miR-124 can prevent  monocyte migration and inflammation by 
targeting CCL2 in pulmonary fibrosis models in mouse [65] and miR-20a is tested to be a negative 
regulator of inflammation in rheumatoid arthritis [66]. TNF-α, IL1β, IL-6 and CCL2 have been 
well established to have a role in the onset and progression of HAND [67-69]. Thus, it will be 
interesting to investigate the effect of candidate miRNAs in targeting cytokines including TNF-α, 
IL-6 and CCL2 in HAND. 
This study aims to investigate the role of specific miRNAs in cytokine expression during 
HAND using HIV-1 infected monocytes/macrophages and microglia. A lentiviral miRNA 
expression vector with the advantage of stable integration and stable expression of target gene [70] 
was used to overexpress miRNA in the cell. The expression of miRNAs were then confirmed by 
both flow cytometry and qPCR as seen in Figure 6. Although scramble was not detectable at 
transcriptional level by qPCR, the scramble miRNA expressing lentivirus transduced cell line has 
more than 95% of eGFP positive cells as detected by flow cytometry. This failure of detection of 
scramble can be due to inefficient design of scramble miRNA specific primers.  
Intracellular analysis of cytokines, TNF-α and IL-8 suggest that miR-20a, miR-106b 
significantly inhibited TNF-α production and miR-106b also reduce IL-8 production in monocytes 
(Figure 7). Follow-up studies to confirm the role of miRNAs to affect cytokines production in the 
supernatant by ELISA suggest that miR-20a, miR-106b were also able to significantly inhibits 
TNF-α production which further support the results from intracellular staining (Figure 9). However, 




estimation in supernatant by ELISA, (Figure 9C) indicating that miRNA mediated effect may have 
a time dependent effect, where the miRNAs can inhibit the cytokine production early during 
induction but may not be sufficient at later stages when increasing amount of IL-8 is secreted. 
Additional experiments are essential to understand this interesting phenomenon.  
To determine whether the tested candidate miRNAs have similar cytokine inhibition effects 
during HIV-1 infection, HIV-1 NL-YU2 virus was used in the study. Previous studies have shown 
that HIV-1 infection increased the production of pro-inflammatory cytokines to promote infection 
and viral replication [71, 72]. Thus, it was not surprising to observe elevated cytokine production 
during HIV-1 infection. Notably, miR-20a, miR-106b consistently showed the function of 
inhibition of TNF-α production, while miR-let-7a was also able to inhibit IL-6 and CCL2 
production (Figure 9), indicating that miRNAs inhibit cytokines production even in the presence 
of HIV-1 infection. These results suggest that the candidate miRNAs can inhibit the 
proinflammatory response amplified by HIV-1 infection.  
Microglia have a major role in HAND pathogenesis, as the resident phagocytic cells, 
microglia support HIV-1 infection and helps in amplification of inflammatory reaction which are 
detrimental for optimal functioning of neurons. The role of candidate miRNAs was evaluated in 
microglia. Results (Figure 10) suggest that miR-20a and miR-106b inhibit IL-6 production upon 
TNF-α stimulation and miR-20a and miR-106b reduce IL-8 production with LPS stimulation, 
while, during HIV-1 infection, miR-20a and miR-106b inhibit IL-8 production. These results 
support our hypothesis that specific candidate miRNAs have a role in controlling cytokines 




explain by the fact that microglia are mainly responsible for the maintenance of the neurons,  
while the macrophages are specialized in phagocytosis of pathogens and antigen presenting role 
thus, lead to different sensitivity between macrophage and microglia towards endotoxins [73]. 
Additionally, other studies in our lab have found similar effects of miRNA on astrocytes, which 
could also contribute to the neuronal protective role of miRNAs in the Macrophage-Microglia-
Astrocytes-Neurons network. 
Exosomes were also evaluated in this study (figure 11) to understand the relationship 
between exosomes and cytokines level. We found that exosomal contents derived from miR-20a, 
miR-106b and miR-let-7a expressing monocytes cell lines showed a reduction of IL-6 and IL-8 
while the corresponding supernatant derived from miR-let-7a and miR-106b cell lines shown the 
cytokines IL-6 and IL-8 are inhibited, respectively. These differences could be due to the time 
kinetics of production/secretion of cytokines regulated by miRNAs.   
Exosome also serve as the delivery machine for miRNA [60]. Thus, it is possible that the 
neuronal protection can be the direct consequence of miRNA delivery though the exosomal 
communication between neuron and support cells like microglia and astrocytes. For this reason, 
future experiment should also focus on the indirect role of miRNAs.  
In addition, the ability of these miRNA expressing monocytes and macrophages to activate 
virus reactivation were also evaluated. In figure 13, all four miRNAs especially miR-106b and 
miR-20a were found to reduce latent HIV-1 reactivation in J-Lat cells. As it shown in figure 12, 
TNF-α was a major host factor responsible for reversal of HIV-1 latency in J-Lat cells. Other 




binding to the NF-kB sites in the LTR [21]. Thus, we believe that miRNAs have a role in inhibition 



































6.0 FUTURE DIRECTIONS 
 
 
Results strongly support that miR-20a and miR-106b have the ability to reduce cytokine 
production in monocytes and microglia cell lines. However, current study only focused on studying 
the function of individual miRNA. Thus, evaluating combinations of candidate miRNAs could be 
utilized to further potentiate the effects of cytokine inhibition. Also, my focus in the current study 
was to evaluate the role of miRNAs on cytokines and chemokines that have previously identified 
to have a major role in HAND pathogenesis. Follow up experiments to evaluate the direct and 
indirect effect of miRNA on neurotoxic and neuroprotective factors will be very useful, similar the 
effect of miRNA in transduced cells and the effect on bystander cells will help to design better 
therapeutics for HAND.  
As previously discussed, miRNA can also directly or indirectly affect HIV-1 virus 
replication and production of viral proteins. In this study, only the function of miRNAs on HIV-1 
host factors have been investigated while the viral factors could also play an important role in the 
neuropathogenesis of HAND. It has been reported that number of miRNAs could direct target 
HIV-1 RNA through base pair complementarity. For example, miR-28 and miR-150 have been 
shown to target the 3′ UTR of viral mRNAs to inhibit viral translation[74]. Thus, future studies 






In addition, the current study utilized monocytes and microglia cell lines to study the effect 
of candidate miRNAs. In future, inclusion of monocytes derived macrophage model will be 
valuable to study the function of candidate miRNAs in primary cells. While in Aim 2, HIV-1 
latency reactivation study was based on the J-lat cell, which is a Jurkat-based T cell line. In vitro 
primary models of HIV-1 latency such as Sahu and Tyagi models could be used to study the effect 
of candidate miRNAs in primary HIV-1 latency models. 
Furthermore, a 3D model of macrophage, microglia and neurons should be developed to 
investigate the role of candidate miRNAs in the Macrophage-Microglia-Astrocytes-Neurons 
network. Thus, we can evaluate the role of candidate miRNAs in 3D CNS organoid in vitro model 
















7.0 PUBLIC HEALTH SIGNIFICANCE 
 
 
HIV-1 infection is a global public health concern and various methods have been developed 
to control the pandemic of HIV-1 infection. Among them, the cART therapy has achieved a great 
success in improving HIV-1 patient life quality. As a result, majority of HIV-1 patients are not 
suffering from acquired immunodeficiency syndrome (AIDS) nowadays, but many of them are 
still experiencing HIV-1 associated comorbidities. Among those comorbidities, HIV associated 
neurocognitive disorder (HAND) is observed in more than half of all HIV-1 patients in a mild 
form in post-cART era. Clinically, the severity of HAND can be divided into three stages: 
asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV 
associated dementia (HAD). The successful coverage of highly active anti-retroviral therapies 
(HAART) has significantly lower the incidence of HAD and MND. However, the ANI remains as 
the most common co-morbidity of HIV-1 infection. Nearly more than half of individuals living 
with HIV-1 infection present with some degree of neuronal impairment. Currently, no treatment 
is available to prevent or treat HAND or ANI. Thus, finding novel methods to manage HAND is 
of public health significance to improve quality of life in HIV-1 population. In this study, miRNAs 
have been introduced and tested to control HAND pathogenesis by reducing specific cytokines 
and chemokines that are critical in neuropathogenesis of HAND. Thus, these miRNAs could have 
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